share_log

Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews

Benzinga ·  Mar 26 09:00

During the last three months, 5 analysts shared their evaluations of Sage Therapeutics (NASDAQ:SAGE), revealing diverse outlooks from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings01400
Last 30D01000
1M Ago00200
2M Ago00200
3M Ago00000

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $26.2, with a high estimate of $29.00 and a low estimate of $22.00. Surpassing the previous average price target of $22.50, the current average has increased by 16.44%.

price target chart

Interpreting Analyst Ratings: A Closer Look

The standing of Sage Therapeutics among financial experts is revealed through an in-depth...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment